UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
UroGen Pharma (Nasdaq: URGN) will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 1:50 PM ET in Boston, MA.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
UroGen Pharma (Nasdaq: URGN) will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 1:50 PM ET in Boston, MA. The presentation includes a formal talk and 1x1 investor meetings.
Webcast access is available on the company website under Events & Presentations, with a replay available for about 30 days.
Details
News Market Reaction – URGN
On Feb 25, the first trading day after this news, URGN closed 0.39% below the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
Key Figures
- Conference dates
- March 2–4, 2026
- TD Cowen 46th Annual Health Care Conference schedule
- Presentation time
- March 3, 2026 at 1:50 PM ET
- URGN management conference presentation slot
- Webcast replay period
- Approximately 30 days
- Duration replay will be available on corporate website
Historical Context
-
Guggenheim biotech summit presentation with webcast and 1x1 investor meetings.
-
Permanent J code J9282 for ZUSDURI to streamline billing and reimbursement.
-
RSU inducement grants to new employees under 2019 Inducement Plan.
-
Piper Sandler healthcare conference fireside chat with webcast access.
-
Q3 2025 results, ZUSDURI launch traction, UGN‑103 data and NDA timeline.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026.
TD Cowen 46th Annual Health Care Conference
| Date / Time: | March 3, 2026, at 1:50 PM ET |
| Format: | Presentation and 1x1 investor meetings |
| Location: | Boston, MA |
| Webcast Link: | here |
The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.